The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation
Official Title: Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)
Study ID: NCT00261378
Brief Summary: The objective of this study is to assess the safety and efficacy of DC Bead™ delivered by intra-arterial embolisation for the treatment of Hepatocellular Carcinoma
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Medizinische Universitat Innsbruck, Innsbruck, , Austria
Allgemines Krankenhaus Vienna, Vienna, , Austria
L'Hopital Beaujon, Clichy, , France
Hopital Claude Huriez, Lille, , France
Groupement Hospitalier Edouard Herriot, Lyon, , France
Hopital Archet II, Nice, , France
Hopital Pitie Salpetriere, Paris, , France
CHU Rangueil, Toulouse, , France
Institut Gustave Roussy, Villejuif, , France
Klinikum der Johann-Wolfgang-Goethe-Universitat, Frankfurt am Main, , Germany
Medicinische Hochschule Hannover, Hannover, , Germany
Klinikum der Johannes Guttenberg, Mainz, , Germany
Fakultat fur Klinische Medizin Mannheim Universitat, Mannheim, , Germany
Inselspital Bern, Bern, , Switzerland
Hopitaux Universitaires de Geneve, Geneve, , Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Universitatsspital Zurich, Zurich, , Switzerland
Name: Prof Johannes Lammer
Affiliation: The Allgemines Krankenhaus, Vienna, 1090, Austria
Role: PRINCIPAL_INVESTIGATOR